Dr. John Powderly, M.D.
Claim this profileCarolina BioOncology Institute
Expert in Solid Tumors
Expert in Cancer
39 reported clinical trials
68 drugs studied
About John Powderly, M.D.
Education:
- Received MD (Doctor of Medicine) from the University of Tennessee in 2006.
Experience:
- Founder and President of Carolina BioOncology Institute, also serving as an Oncologist.
- Focuses on Phase I immunotherapy clinical trials and cancer research.
- Manages on-site clinical laboratory services, including hematology and immunology.
- Specializes in translational tumor immunology research.
Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
2Cancer
Global LeaderStage IV
Stage III
EphA5 positive
Affiliated Hospitals
Clinical Trials John Powderly, M.D. is currently running
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
CLN-619 + Pembrolizumab
for Cancer
This trial is testing a new drug called CLN-619 alone and with pembrolizumab in patients with advanced solid tumors. These patients may not have other treatment options. Pembrolizumab helps the immune system fight cancer, and they are seeing if CLN-619 can help too.
Recruiting1 award Phase 110 criteria
More about John Powderly, M.D.
Clinical Trial Related3 years of experience running clinical trials · Led 39 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments John Powderly, M.D. has experience with
- Pembrolizumab
- Nivolumab
- Docetaxel
- Toripalimab
- Cetuximab
- MBRC-101
Breakdown of trials John Powderly, M.D. has run
Solid Tumors
Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does John Powderly, M.D. specialize in?
Is John Powderly, M.D. currently recruiting for clinical trials?
Are there any treatments that John Powderly, M.D. has studied deeply?
What is the best way to schedule an appointment with John Powderly, M.D.?
What is the office address of John Powderly, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.